Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-11 (month) in 4mo
ESTIMATED |
READOUT
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharma
Phase 1/2 · Leukemia, Myeloid, Acute, Refractory AML |
APTOF Aptose Biosciences Inc. | Tuspetinib, Venetoclax Oral Tablet, Azac |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|